Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| human origin | 5246 | 1350289-85-8 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Guselkumab is a human monoclonal IgG1-lambda antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Guselkumab inhibits the release of proinflammatory cytokines and chemokines.
|
| Dose | Unit | Route |
|---|---|---|
| 1.79 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 10, 2017 | EMA | Janssen-Cilag International N.V. | |
| March 23, 2018 | PMDA | Janssen Pharmaceutical KK | |
| July 13, 2017 | FDA | JANSSEN BIOTECH |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 7540.80 | 22.83 | 2581 | 14910 | 289106 | 90321850 |
| Accidental exposure to product | 2468.39 | 22.83 | 707 | 16784 | 41659 | 90569297 |
| Needle issue | 1852.17 | 22.83 | 448 | 17043 | 13486 | 90597470 |
| Device malfunction | 1299.45 | 22.83 | 368 | 17123 | 20609 | 90590347 |
| Device issue | 1234.04 | 22.83 | 382 | 17109 | 29155 | 90581801 |
| Product leakage | 1115.05 | 22.83 | 199 | 17292 | 1209 | 90609747 |
| Drug delivery system malfunction | 948.40 | 22.83 | 173 | 17318 | 1208 | 90609748 |
| Device defective | 816.48 | 22.83 | 178 | 17313 | 3308 | 90607648 |
| Device deployment issue | 797.97 | 22.83 | 186 | 17305 | 4723 | 90606233 |
| Device leakage | 657.61 | 22.83 | 184 | 17307 | 9807 | 90601149 |
| Product storage error | 556.83 | 22.83 | 191 | 17300 | 20050 | 90590906 |
| Syringe issue | 387.40 | 22.83 | 100 | 17391 | 3902 | 90607054 |
| Drug ineffective | 258.87 | 22.83 | 712 | 16779 | 1383586 | 89227370 |
| Underdose | 258.28 | 22.83 | 149 | 17342 | 53868 | 90557088 |
| Inappropriate schedule of product administration | 228.17 | 22.83 | 206 | 17285 | 149727 | 90461229 |
| Liquid product physical issue | 196.11 | 22.83 | 48 | 17443 | 1502 | 90609454 |
| COVID-19 | 183.63 | 22.83 | 193 | 17298 | 168650 | 90442306 |
| Psoriasis | 155.47 | 22.83 | 166 | 17325 | 147588 | 90463368 |
| Therapy interrupted | 150.58 | 22.83 | 103 | 17388 | 50005 | 90560951 |
| Injection site haemorrhage | 109.01 | 22.83 | 68 | 17423 | 28250 | 90582706 |
| Device delivery system issue | 108.98 | 22.83 | 31 | 17460 | 1747 | 90609209 |
| Drug dose omission by device | 91.50 | 22.83 | 43 | 17448 | 10188 | 90600768 |
| Product quality issue | 88.46 | 22.83 | 92 | 17399 | 79233 | 90531723 |
| Incorrect dose administered | 74.79 | 22.83 | 84 | 17407 | 78846 | 90532110 |
| Psoriatic arthropathy | 65.00 | 22.83 | 139 | 17352 | 228196 | 90382760 |
| Product complaint | 63.81 | 22.83 | 37 | 17454 | 13463 | 90597493 |
| Injection site reaction | 62.82 | 22.83 | 83 | 17408 | 91997 | 90518959 |
| Injection site pain | 58.02 | 22.83 | 113 | 17378 | 173586 | 90437370 |
| Lung adenocarcinoma stage IV | 57.25 | 22.83 | 14 | 17477 | 436 | 90610520 |
| Pneumonia | 57.24 | 22.83 | 259 | 17232 | 637800 | 89973156 |
| Therapy cessation | 57.23 | 22.83 | 51 | 17440 | 36310 | 90574646 |
| Product temperature excursion issue | 56.50 | 22.83 | 16 | 17475 | 887 | 90610069 |
| Confusional state | 56.17 | 22.83 | 5 | 17486 | 386200 | 90224756 |
| Breast cancer | 55.74 | 22.83 | 60 | 17431 | 53701 | 90557255 |
| Paternal exposure during pregnancy | 55.64 | 22.83 | 13 | 17478 | 332 | 90610624 |
| Product packaging issue | 55.05 | 22.83 | 18 | 17473 | 1623 | 90609333 |
| Synovitis | 51.58 | 22.83 | 3 | 17488 | 329749 | 90281207 |
| Incorrect dose administered by device | 50.95 | 22.83 | 24 | 17467 | 5713 | 90605243 |
| Exposure during pregnancy | 49.17 | 22.83 | 128 | 17363 | 238282 | 90372674 |
| Wound | 43.83 | 22.83 | 4 | 17487 | 302976 | 90307980 |
| General physical health deterioration | 41.37 | 22.83 | 9 | 17482 | 355106 | 90255850 |
| Toxicity to various agents | 41.11 | 22.83 | 4 | 17487 | 287842 | 90323114 |
| Systemic lupus erythematosus | 40.51 | 22.83 | 10 | 17481 | 361886 | 90249070 |
| Product label issue | 38.04 | 22.83 | 12 | 17479 | 964 | 90609992 |
| Surgery | 37.84 | 22.83 | 45 | 17446 | 44842 | 90566114 |
| Asthenia | 37.41 | 22.83 | 29 | 17462 | 533722 | 90077234 |
| Dyspnoea | 37.30 | 22.83 | 71 | 17420 | 880884 | 89730072 |
| Drug delivery system issue | 36.54 | 22.83 | 8 | 17483 | 151 | 90610805 |
| Device mechanical issue | 36.39 | 22.83 | 12 | 17479 | 1111 | 90609845 |
| Infusion related reaction | 35.60 | 22.83 | 18 | 17473 | 416762 | 90194194 |
| Anaemia | 35.35 | 22.83 | 12 | 17479 | 352790 | 90258166 |
| Drug intolerance | 34.41 | 22.83 | 22 | 17469 | 447569 | 90163387 |
| Arthropathy | 34.11 | 22.83 | 14 | 17477 | 366228 | 90244728 |
| Gait disturbance | 33.79 | 22.83 | 5 | 17486 | 260491 | 90350465 |
| Arthralgia | 33.73 | 22.83 | 261 | 17230 | 778261 | 89832695 |
| Acute kidney injury | 33.69 | 22.83 | 10 | 17481 | 320377 | 90290579 |
| Illness | 33.22 | 22.83 | 58 | 17433 | 81911 | 90529045 |
| Maternal exposure during pregnancy | 33.15 | 22.83 | 14 | 17477 | 360049 | 90250907 |
| Physical product label issue | 33.11 | 22.83 | 6 | 17485 | 40 | 90610916 |
| Hypotension | 32.72 | 22.83 | 11 | 17480 | 325386 | 90285570 |
| Decreased appetite | 32.55 | 22.83 | 16 | 17475 | 376524 | 90234432 |
| Drug hypersensitivity | 31.46 | 22.83 | 26 | 17465 | 463583 | 90147373 |
| Intentional product use issue | 31.00 | 22.83 | 3 | 17488 | 216889 | 90394067 |
| Stomatitis | 29.95 | 22.83 | 8 | 17483 | 274690 | 90336266 |
| Skin burning sensation | 29.85 | 22.83 | 27 | 17464 | 19584 | 90591372 |
| Fatigue | 28.82 | 22.83 | 120 | 17371 | 1153903 | 89457053 |
| Injection related reaction | 28.75 | 22.83 | 10 | 17481 | 1089 | 90609867 |
| Abdominal discomfort | 28.58 | 22.83 | 30 | 17461 | 477298 | 90133658 |
| Wrong technique in product usage process | 28.17 | 22.83 | 50 | 17441 | 71521 | 90539435 |
| Constipation | 27.29 | 22.83 | 10 | 17481 | 280385 | 90330571 |
| Contraindicated product administered | 27.07 | 22.83 | 14 | 17477 | 320125 | 90290831 |
| Irritable bowel syndrome | 26.86 | 22.83 | 4 | 17487 | 207444 | 90403512 |
| Swelling | 26.62 | 22.83 | 25 | 17466 | 419033 | 90191923 |
| Folliculitis | 26.32 | 22.83 | 4 | 17487 | 204349 | 90406607 |
| Insomnia | 26.16 | 22.83 | 16 | 17475 | 333458 | 90277498 |
| Spinal operation | 26.06 | 22.83 | 19 | 17472 | 10177 | 90600779 |
| Fall | 25.90 | 22.83 | 33 | 17458 | 481777 | 90129179 |
| Joint swelling | 25.51 | 22.83 | 36 | 17455 | 503264 | 90107692 |
| Device occlusion | 25.33 | 22.83 | 18 | 17473 | 9264 | 90601692 |
| Reactive gastropathy | 25.32 | 22.83 | 8 | 17483 | 646 | 90610310 |
| Impaired healing | 25.19 | 22.83 | 7 | 17484 | 234192 | 90376764 |
| Drug interaction | 25.04 | 22.83 | 11 | 17480 | 276442 | 90334514 |
| Musculoskeletal stiffness | 25.02 | 22.83 | 13 | 17478 | 296519 | 90314437 |
| Product administration error | 24.80 | 22.83 | 28 | 17463 | 26395 | 90584561 |
| Hypoaesthesia | 24.75 | 22.83 | 15 | 17476 | 314195 | 90296761 |
| Discomfort | 24.71 | 22.83 | 11 | 17480 | 274324 | 90336632 |
| Nail psoriasis | 24.53 | 22.83 | 8 | 17483 | 715 | 90610241 |
| Fibromyalgia | 24.47 | 22.83 | 5 | 17486 | 206264 | 90404692 |
| Pericarditis | 24.07 | 22.83 | 11 | 17480 | 270140 | 90340816 |
| Wheezing | 24.01 | 22.83 | 8 | 17483 | 238072 | 90372884 |
| Oedema peripheral | 23.77 | 22.83 | 10 | 17481 | 257905 | 90353051 |
| Frostbite | 23.54 | 22.83 | 6 | 17485 | 222 | 90610734 |
| Oedema | 23.46 | 22.83 | 5 | 17486 | 200290 | 90410666 |
| Dyspepsia | 23.10 | 22.83 | 5 | 17486 | 198155 | 90412801 |
| Thrombocytopenia | 22.89 | 22.83 | 6 | 17485 | 208719 | 90402237 |
| Vomiting | 22.87 | 22.83 | 77 | 17414 | 788216 | 89822740 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 5954.82 | 31.00 | 2003 | 9604 | 152362 | 42457366 |
| Accidental exposure to product | 1555.15 | 31.00 | 453 | 11154 | 19940 | 42589788 |
| Needle issue | 1480.59 | 31.00 | 365 | 11242 | 8362 | 42601366 |
| Device deployment issue | 983.83 | 31.00 | 168 | 11439 | 487 | 42609241 |
| Device issue | 828.02 | 31.00 | 254 | 11353 | 13255 | 42596473 |
| Product leakage | 682.34 | 31.00 | 127 | 11480 | 675 | 42609053 |
| Device malfunction | 672.10 | 31.00 | 212 | 11395 | 12115 | 42597613 |
| Drug delivery system malfunction | 606.76 | 31.00 | 107 | 11500 | 394 | 42609334 |
| Device defective | 510.03 | 31.00 | 113 | 11494 | 1575 | 42608153 |
| Product storage error | 454.80 | 31.00 | 154 | 11453 | 10986 | 42598742 |
| Device leakage | 438.89 | 31.00 | 147 | 11460 | 10138 | 42599590 |
| Underdose | 248.89 | 31.00 | 111 | 11496 | 16555 | 42593173 |
| Inappropriate schedule of product administration | 238.69 | 31.00 | 202 | 11405 | 95700 | 42514028 |
| Drug ineffective | 206.67 | 31.00 | 496 | 11111 | 629701 | 41980027 |
| Syringe issue | 187.93 | 31.00 | 75 | 11532 | 8481 | 42601247 |
| Liquid product physical issue | 178.81 | 31.00 | 42 | 11565 | 767 | 42608961 |
| Psoriasis | 134.45 | 31.00 | 109 | 11498 | 48495 | 42561233 |
| Product quality issue | 98.20 | 31.00 | 61 | 11546 | 17821 | 42591907 |
| Psoriatic arthropathy | 97.86 | 31.00 | 69 | 11538 | 24898 | 42584830 |
| Drug dose omission by device | 80.80 | 31.00 | 37 | 11570 | 5849 | 42603879 |
| Therapy interrupted | 68.10 | 31.00 | 53 | 11554 | 22197 | 42587531 |
| Injection site haemorrhage | 66.88 | 31.00 | 41 | 11566 | 11695 | 42598033 |
| Device delivery system issue | 65.50 | 31.00 | 20 | 11587 | 1017 | 42608711 |
| Acute kidney injury | 62.93 | 31.00 | 12 | 11595 | 367325 | 42242403 |
| Arthralgia | 54.36 | 31.00 | 150 | 11457 | 205088 | 42404640 |
| COVID-19 | 54.19 | 31.00 | 106 | 11501 | 115842 | 42493886 |
| Therapeutic product effect decreased | 51.00 | 31.00 | 58 | 11549 | 39092 | 42570636 |
| Drug interaction | 49.51 | 31.00 | 7 | 11600 | 266992 | 42342736 |
| Anaemia | 48.28 | 31.00 | 9 | 11598 | 280269 | 42329459 |
| Product packaging issue | 45.02 | 31.00 | 14 | 11593 | 757 | 42608971 |
| Product complaint | 44.94 | 31.00 | 25 | 11582 | 5952 | 42603776 |
| Therapy cessation | 42.52 | 31.00 | 39 | 11568 | 20411 | 42589317 |
| Hypotension | 40.84 | 31.00 | 10 | 11597 | 257621 | 42352107 |
| Delusion of parasitosis | 40.35 | 31.00 | 9 | 11598 | 129 | 42609599 |
| Neutropenia | 37.49 | 31.00 | 5 | 11602 | 199426 | 42410302 |
| Incorrect dose administered | 37.21 | 31.00 | 58 | 11549 | 52916 | 42556812 |
| Device mechanical issue | 36.31 | 31.00 | 13 | 11594 | 1088 | 42608640 |
| Angioimmunoblastic T-cell lymphoma | 36.00 | 31.00 | 10 | 11597 | 363 | 42609365 |
| Treatment failure | 35.17 | 31.00 | 62 | 11545 | 62562 | 42547166 |
| Product temperature excursion issue | 33.39 | 31.00 | 10 | 11597 | 476 | 42609252 |
| Asthenia | 32.58 | 31.00 | 18 | 11589 | 280775 | 42328953 |
| Pruritus | 31.65 | 31.00 | 118 | 11489 | 188653 | 42421075 |
| Nausea | 31.62 | 31.00 | 37 | 11570 | 396762 | 42212966 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 10185.93 | 22.78 | 3289 | 17462 | 318493 | 110250055 |
| Accidental exposure to product | 3029.75 | 22.78 | 855 | 19896 | 49153 | 110519395 |
| Needle issue | 2756.45 | 22.78 | 644 | 20107 | 17196 | 110551352 |
| Product leakage | 1551.89 | 22.78 | 268 | 20483 | 1350 | 110567198 |
| Device issue | 1542.26 | 22.78 | 467 | 20284 | 34068 | 110534480 |
| Drug delivery system malfunction | 1349.65 | 22.78 | 223 | 20528 | 812 | 110567736 |
| Device malfunction | 1280.96 | 22.78 | 378 | 20373 | 25180 | 110543368 |
| Device deployment issue | 1091.76 | 22.78 | 233 | 20518 | 4020 | 110564528 |
| Product storage error | 897.45 | 22.78 | 277 | 20474 | 21451 | 110547097 |
| Device defective | 877.28 | 22.78 | 191 | 20560 | 3631 | 110564917 |
| Device leakage | 672.70 | 22.78 | 207 | 20544 | 15841 | 110552707 |
| Syringe issue | 391.16 | 22.78 | 121 | 20630 | 9404 | 110559144 |
| Underdose | 332.12 | 22.78 | 184 | 20567 | 63370 | 110505178 |
| Inappropriate schedule of product administration | 323.32 | 22.78 | 283 | 20468 | 203354 | 110365194 |
| Liquid product physical issue | 322.98 | 22.78 | 72 | 20679 | 1528 | 110567020 |
| Psoriasis | 259.91 | 22.78 | 213 | 20538 | 139780 | 110428768 |
| COVID-19 | 220.29 | 22.78 | 250 | 20501 | 244810 | 110323738 |
| Therapy interrupted | 198.48 | 22.78 | 121 | 20630 | 49701 | 110518847 |
| Injection site haemorrhage | 165.27 | 22.78 | 93 | 20658 | 32935 | 110535613 |
| Product quality issue | 142.02 | 22.78 | 117 | 20634 | 77182 | 110491366 |
| Product complaint | 100.09 | 22.78 | 50 | 20701 | 13922 | 110554626 |
| Drug ineffective | 91.41 | 22.78 | 540 | 20211 | 1520000 | 109048548 |
| Pneumonia | 90.57 | 22.78 | 364 | 20387 | 876350 | 109692198 |
| Psoriatic arthropathy | 87.83 | 22.78 | 143 | 20608 | 196618 | 110371930 |
| Product packaging issue | 84.80 | 22.78 | 25 | 20726 | 1646 | 110566902 |
| Incorrect dose administered | 78.47 | 22.78 | 97 | 20654 | 103544 | 110465004 |
| Toxicity to various agents | 73.89 | 22.78 | 4 | 20747 | 480551 | 110087997 |
| Injection site pain | 73.61 | 22.78 | 125 | 20626 | 177797 | 110390751 |
| Acute kidney injury | 73.40 | 22.78 | 15 | 20736 | 635415 | 109933133 |
| Therapy cessation | 72.30 | 22.78 | 63 | 20688 | 44794 | 110523754 |
| Hypotension | 63.39 | 22.78 | 11 | 20740 | 523838 | 110044710 |
| Confusional state | 63.39 | 22.78 | 7 | 20744 | 468673 | 110099875 |
| Anaemia | 60.95 | 22.78 | 14 | 20737 | 547072 | 110021476 |
| Product temperature excursion issue | 57.88 | 22.78 | 16 | 20735 | 835 | 110567713 |
| Drug interaction | 51.50 | 22.78 | 15 | 20736 | 500168 | 110068380 |
| Incorrect dose administered by device | 50.62 | 22.78 | 25 | 20726 | 6789 | 110561759 |
| Asthenia | 50.09 | 22.78 | 34 | 20717 | 688965 | 109879583 |
| Drug intolerance | 48.15 | 22.78 | 9 | 20742 | 406503 | 110162045 |
| Dyspnoea | 48.03 | 22.78 | 84 | 20667 | 1106788 | 109461760 |
| Lung adenocarcinoma stage IV | 44.73 | 22.78 | 12 | 20739 | 559 | 110567989 |
| Illness | 44.00 | 22.78 | 65 | 20686 | 82106 | 110486442 |
| General physical health deterioration | 41.54 | 22.78 | 14 | 20737 | 425281 | 110143267 |
| Neutropenia | 40.88 | 22.78 | 10 | 20741 | 374610 | 110193938 |
| Decreased appetite | 38.01 | 22.78 | 21 | 20730 | 475825 | 110092723 |
| Drug delivery system issue | 37.97 | 22.78 | 9 | 20742 | 252 | 110568296 |
| Physical product label issue | 37.93 | 22.78 | 7 | 20744 | 54 | 110568494 |
| Delusion of parasitosis | 37.77 | 22.78 | 9 | 20742 | 258 | 110568290 |
| Breast cancer | 37.40 | 22.78 | 41 | 20710 | 38501 | 110530047 |
| Synovitis | 37.27 | 22.78 | 4 | 20747 | 274088 | 110294460 |
| Arthralgia | 36.13 | 22.78 | 260 | 20491 | 779372 | 109789176 |
| Wrong technique in product usage process | 35.60 | 22.78 | 61 | 20690 | 87287 | 110481261 |
| Poor quality product administered | 34.39 | 22.78 | 17 | 20734 | 4624 | 110563924 |
| Stomatitis | 34.18 | 22.78 | 5 | 20746 | 270237 | 110298311 |
| Angioimmunoblastic T-cell lymphoma | 34.13 | 22.78 | 10 | 20741 | 644 | 110567904 |
| Product label issue | 33.78 | 22.78 | 11 | 20740 | 1007 | 110567541 |
| Vomiting | 33.52 | 22.78 | 76 | 20675 | 910599 | 109657949 |
| Mobility decreased | 33.50 | 22.78 | 3 | 20748 | 237419 | 110331129 |
| Surgery | 33.44 | 22.78 | 40 | 20711 | 41243 | 110527305 |
| Spinal operation | 32.19 | 22.78 | 22 | 20729 | 10950 | 110557598 |
| Device mechanical issue | 29.82 | 22.78 | 12 | 20739 | 2012 | 110566536 |
| Completed suicide | 29.48 | 22.78 | 5 | 20746 | 242376 | 110326172 |
| Nausea | 29.29 | 22.78 | 126 | 20625 | 1235564 | 109332984 |
| Contraindicated product administered | 28.33 | 22.78 | 6 | 20745 | 248261 | 110320287 |
| Intentional product use issue | 28.27 | 22.78 | 6 | 20745 | 247900 | 110320648 |
| Overdose | 28.05 | 22.78 | 5 | 20746 | 233789 | 110334759 |
| Drug hypersensitivity | 27.26 | 22.78 | 27 | 20724 | 454063 | 110114485 |
| Insomnia | 27.24 | 22.78 | 17 | 20734 | 360573 | 110207975 |
| Product administration error | 26.82 | 22.78 | 34 | 20717 | 37183 | 110531365 |
| Off label use | 26.46 | 22.78 | 411 | 20340 | 1499774 | 109068774 |
| Oedema | 26.28 | 22.78 | 4 | 20747 | 209972 | 110358576 |
| Device delivery system issue | 25.85 | 22.78 | 11 | 20740 | 2122 | 110566426 |
| Gait disturbance | 25.72 | 22.78 | 10 | 20741 | 278198 | 110290350 |
| Wheezing | 25.61 | 22.78 | 8 | 20743 | 255222 | 110313326 |
| Systemic lupus erythematosus | 25.47 | 22.78 | 8 | 20743 | 254330 | 110314218 |
| Infusion related reaction | 24.85 | 22.78 | 21 | 20730 | 381141 | 110187407 |
| Wrong schedule | 24.79 | 22.78 | 8 | 20743 | 712 | 110567836 |
| Product dispensing error | 24.42 | 22.78 | 22 | 20729 | 16323 | 110552225 |
| Blood cholesterol increased | 24.36 | 22.78 | 3 | 20748 | 184782 | 110383766 |
| Product packaging quantity issue | 24.23 | 22.78 | 10 | 20741 | 1789 | 110566759 |
| Wound | 24.16 | 22.78 | 7 | 20744 | 234430 | 110334118 |
| Pancytopenia | 24.05 | 22.78 | 5 | 20746 | 209608 | 110358940 |
| Hypokalaemia | 23.95 | 22.78 | 3 | 20748 | 182445 | 110386103 |
| Pustule | 23.51 | 22.78 | 12 | 20739 | 3492 | 110565056 |
| Cellulitis | 23.41 | 22.78 | 64 | 20687 | 125952 | 110442596 |
| Dermatitis exfoliative generalised | 23.09 | 22.78 | 18 | 20733 | 10954 | 110557594 |
| Drug abuse | 23.09 | 22.78 | 3 | 20748 | 177408 | 110391140 |
| Dyspepsia | 23.09 | 22.78 | 4 | 20747 | 190961 | 110377587 |
| Thrombocytopenia | 23.01 | 22.78 | 19 | 20732 | 348866 | 110219682 |
| Respiratory failure | 22.99 | 22.78 | 6 | 20745 | 215326 | 110353222 |
| Tachycardia | 22.93 | 22.78 | 7 | 20744 | 226638 | 110341910 |
| Pyrexia | 22.87 | 22.78 | 89 | 20662 | 898176 | 109670372 |
| Oedema peripheral | 22.81 | 22.78 | 17 | 20734 | 328643 | 110239905 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AC16 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors |
| FDA MoA | N0000192798 | Interleukin-23 Antagonists |
| FDA EPC | N0000192799 | Interleukin-23 Antagonist |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Palmoplantar pustulosis | indication | 27520001 | DOID:4398 |
| Plaque psoriasis | indication | 200965009 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Interleukin-23 | Cytokine | ANTIBODY BINDING | UNKNOWN | DRUG LABEL |
| ID | Source |
|---|---|
| 089658A12D | UNII |
| 4036845 | VANDF |
| C3852217 | UMLSCUI |
| CHEBI:754996 | CHEBI |
| CHEMBL2364648 | ChEMBL_ID |
| DB11834 | DRUGBANK_ID |
| D10438 | KEGG_DRUG |
| 9774 | INN_ID |
| C000588857 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7998 | IUPHAR_LIGAND_ID |
| 736494008 | SNOMEDCT_US |
| 763578000 | SNOMEDCT_US |
| 259984 | MMSL |
| 32911 | MMSL |
| d08615 | MMSL |
| 017278 | NDDF |
| 1928588 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TREMFYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-640 | INJECTION | 100 mg | SUBCUTANEOUS | BLA | 31 sections |
| TREMFYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-640 | INJECTION | 100 mg | SUBCUTANEOUS | BLA | 31 sections |
| TREMFYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-650 | INJECTION | 200 mg | INTRAVENOUS | BLA | 31 sections |
| TREMFYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-650 | INJECTION | 200 mg | INTRAVENOUS | BLA | 31 sections |
| TREMFYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-651 | INJECTION | 200 mg | SUBCUTANEOUS | BLA | 31 sections |
| TREMFYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-651 | INJECTION | 200 mg | SUBCUTANEOUS | BLA | 31 sections |